The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.

AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

AbbVie is a strong investment opportunity with growth potential, dividend income, and a diverse drug portfolio. Find out why ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Bitcoin price touched a new high amid clues as to how President-elect Trump may create a strategic reserve.

24.5 46.4 (21.9) - CH / 800 m / tf / 2 bt 7 / S H Wang / Slow canter site (R.B.) (CH) ...